The largest study ever to look at why an expensive and commonly used group of drugs fails patients with Crohn's disease has concluded that standardised drug doses are often too low.
Feb 27, 2019
0
83
(HealthDay)—For patients with acute severe ulcerative colitis (ASUC), the baseline Mayo Endoscopic Score and the C-reactive protein (CRP)/albumin ratio predict treatment response to infliximab, according to research published ...
Jan 3, 2018
0
1
In patients with inflammatory bowel disease (IBD), the body attacks the lining of the digestive tract. Up to half of patients who benefit from the first-line anti-inflammatory drug infliximab eventually stop responding to ...
Oct 3, 2017
0
0
(HealthDay)—For patients with inflammatory bowel disease (IBD), infliximab and/or azathioprine treatment is associated with poor response rate to hepatitis B virus (HBV) vaccination, according to a study published in the ...
Oct 21, 2015
0
9
(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, according to a study published ...
Sep 2, 2015
0
16
(HealthDay)—For patients with moderate to severely active ulcerative colitis (UC), clinical nonresponders to infliximab have high concentrations of infliximab in fecal samples, according to a study published in the August ...
Aug 5, 2015
0
31
Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient's chances of having a long-term successful response to therapy, a pilot ...
Sep 11, 2014
0
0
(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study ...
Jul 28, 2014
0
0
(HealthDay)—Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds.
Jul 1, 2013
0
0
Treatment with a biological agent was not superior to conventional treatment in terms of the effect on work loss over 21 months in patients with early rheumatoid arthritis (RA) who responded insufficiently to methotrexate, ...
Jul 1, 2013
0
0
